Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis
- PMID: 15755326
- PMCID: PMC555545
- DOI: 10.1186/1476-0711-4-5
Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis
Abstract
Background: Antimicrobial therapy is considered an important component in the medical management of most patients with acute exacerbation of chronic bronchitis (AECB). The three predominant bacterial species isolated are nontypeable Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Staphylococcus aureus is also frequently isolated while atypical bacteria are thought to cause up to 10% of exacerbations. Antibacterial resistance is increasing worldwide and little surveillance data exist concerning pathogens isolated from patients with AECB.
Methods: This study examines the prevalence of antibacterial resistance in isolates obtained from patients with clinically diagnosed AECB. A total of 3043 isolates were obtained from 85 centres in 29 countries, between 1999-2003, and were tested against the new ketolide telithromycin and a panel of commonly used antibiotics.
Results and discussion: Of the S. pneumoniae isolates, 99.9% were susceptible to telithromycin, but only 71% were susceptible to erythromycin and 75.3% to penicillin. Of the H. influenzae isolates, 99.6% were susceptible to telithromycin. 11.7% of these isolates produced beta-lactamase. Almost 10% of S. pneumoniae were multidrug-resistant; 99.0% of these isolates were susceptible to telithromycin. Telithromycin also demonstrated good in vitro activity against M. catarrhalis (MIC90 = 0.12 mg/L) and was the most active compound against methicillin-susceptible S. aureus (98.9% susceptible).
Conclusion: Telithromycin demonstrated similar or better activity against the bacterial species investigated than the other agents, with the most complete coverage overall. These species are the predominant causative bacterial pathogens in AECB and thus the spectrum of activity of telithromycin makes it a potential alternative for the empirical treatment of AECB.
Similar articles
-
Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.J Antimicrob Chemother. 2004 May;53(5):793-6. doi: 10.1093/jac/dkh178. Epub 2004 Mar 31. J Antimicrob Chemother. 2004. PMID: 15056640
-
Discrepancy between antibiotics administered in acute exacerbations of chronic bronchitis and susceptibility of isolated pathogens in respiratory samples: multicentre study in the primary care setting.Int J Antimicrob Agents. 2006 Nov;28(5):472-6. doi: 10.1016/j.ijantimicag.2006.05.034. Int J Antimicrob Agents. 2006. PMID: 17046209
-
Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003-2004).Diagn Microbiol Infect Dis. 2009 Mar;63(3):302-8. doi: 10.1016/j.diagmicrobio.2008.11.012. Epub 2009 Jan 9. Diagn Microbiol Infect Dis. 2009. PMID: 19135821
-
Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.Clin Infect Dis. 2005 Jun 1;40(11):1657-64. doi: 10.1086/430067. Epub 2005 Apr 22. Clin Infect Dis. 2005. PMID: 15889365 Review.
-
Telithromycin: the first ketolide antimicrobial.Clin Ther. 2005 Aug;27(8):1144-63. doi: 10.1016/j.clinthera.2005.08.009. Clin Ther. 2005. PMID: 16199242 Review.
Cited by
-
In vitro activity of telithromycin against Haemophilus influenzae at epithelial lining fluid concentrations.BMC Microbiol. 2008 Jan 29;8:23. doi: 10.1186/1471-2180-8-23. BMC Microbiol. 2008. PMID: 18230154 Free PMC article.
References
-
- WHO . The World Health Report 2002. Reducing risks, promoting healthy life. MDI.WHR.202.A. Geneva , The World Health Organization; 2002. - PubMed
-
- Gross NJ. The GOLD standard for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1047–1048. - PubMed
-
- GOLD Global Initiative for Chronic Obstructive Lung Disease. http://wwwgoldcopdcom/ 2003.
-
- ATS Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med. 1995;152:S77–121. - PubMed
-
- Gump DW, Phillips CA, Forsyth BR, McIntosh K, Lamborn KR, Stouch WH. Role of infection in chronic bronchitis. Am Rev Respir Dis. 1976;113:465–474. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical